2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen

BACKGROUND: Three-drug regimens (3DRs) have long been the mainstay of antiretroviral treatment (ART) for HIV. Dolutegravir-based two-drug regimens (DTG 2DRs) are now accepted alternatives to 3DRs, with the first 2DR single tablet regimen (STR), Juluca (DTG/rilpivirine [RPV]), FDA-approved in 2017. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Douglas, Scheibel, Steven F, Ramgopal, Moti, Riedel, David J, Garris, Cindy, Oglesby, Alan, Waller, John E, Roberts, Jenna, Mycock, Katie L, Dhir, Shelly, Bonnie, Collins, Megan, Dominguez, Mrus, Joseph, Pike, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810796/
http://dx.doi.org/10.1093/ofid/ofz360.2163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810796/
http://dx.doi.org/10.1093/ofid/ofz360.2163

Ejemplares similares